摘要
目的:探讨切除修复交叉互补基因1(ERCC1)Asn118Asn(C→T,rs11615)多态性与中国汉族晚期胃癌患者对奥沙利铂一线化疗效果的关系。方法:71例晚期胃癌患者化疗前抽静脉血提取DNA,以real-time PCR法对ERCC1基因进行SNP分型。患者接受奥沙利铂化疗,观察疾病控制率(CR+PR+SD)及至肿瘤进展时间(TTP),并比较不同基因型与疗效的关系。结果:47例Ⅳ期胃癌患者可以评价化疗疗效,疾病控制率为55.3%,C/C与C/T+T/T基因型在疾病控制组和无效组之间分布无统计学意义(χ2=2.755,P=0.097)。71例晚期胃癌患者中位TTP为6个月,C/T+T/T基因型患者其中位TTP为5个月,与纯合基因型C/C中位TTP 6个月相比,差异无统计学意义(OR=0.615,P=0.071)。其中24例Ⅲ期胃癌患者中位TTP为8个月,C/T+T/T型患者中位TTP为7个月,与纯合基因型C/C中位TTP 8个月相比,差异无统计学意义(OR=0.397,P=0.111)。结论:ERCC1 Asn118Asn基因多态性与中国汉族晚期胃癌患者接受奥沙利铂一线化疗后的临床效果有相关趋势,需要进一步观察论证。
Objective：To assess the effect of the polymorphism of ERCC1 Asnll8Asn （C→T,rs11615） on treatment response and TTP of advanced gastric cancer patients treated with oxaliplatin as first-fine chemotherapy regimen. Methods： DNA was extracted from peripheral venous blood before chemotherapy from 71 advanced gastric cancer patients. Real-time PCR was used for genotyping. ERCC1 genotypes were analyzed for associations with disease control response （DCR） and time to progression （＇ITP）. Results：The DCR of 47 stage IV cases was 55. 3%. In this subgroup, patients with C/C genotype did not show distinctly preponderance compared to those with C/T ＋ T/T, between response group （ CR ＋ PR ＋ SD） and un-response group （PD） （ X2 = 2. 755,P = 0. 097）. The median TIP for all 71 patients was 6 months, patients possessing C/C genotype showed a median TIP of 6 months, was not significantly different from 5 months in patients with C/T ＋ T/T genotype（ OR =0. 615 ,P =0. 071 ）. The median TFP for 24 patients in stage m was S months. Among them, patients possessing C/C genotype showed a median TTP of 8 months, slightly differed with 7 months in patients with C/T ＋ T/T genotypes, but the difference was not significant （ OR = 0. 397, P = 0. 111 ）. Conclusion： The results suggest that the ERCCI Asn118Asn genetic polymorphisms may be associated with clinical outcomes of Chinese patients with advanced gastric cancer accepted oxaliplatin as first-line chemotherapy, but need further observation and demonstration.
出处
《临床肿瘤学杂志》
CAS
2009年第9期792-796,共5页
Chinese Clinical Oncology
关键词
胃癌
基因多态性
药物遗传学
切除修复交叉互补基因1
奥沙利铂
Gastric neoplasms
Gene polymorphism
Pharmacogenetics
Excision repair cross-complementation group 1
Oxaliplatin
